145 related articles for article (PubMed ID: 21677485)
1. Efficacy and toxicity of S-1 plus cisplatin combination neoadjuvant chemotherapy in patients with oral cancer.
Kawasaki G; Yoshitomi I; Yanamoto S; Yamada S; Mizuno A
Gan To Kagaku Ryoho; 2011 Jun; 38(6):951-7. PubMed ID: 21677485
[TBL] [Abstract][Full Text] [Related]
2. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.
Harada K; Kawashima Y; Yoshida H; Sato M
Oncol Rep; 2006 Jun; 15(6):1417-23. PubMed ID: 16685374
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical and clinicopathological study of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase expression in oral cancer patients responding to UFT].
Kawasaki G; Yoshitomi I; Yanamoto S; Yamada S; Kawano T; Mizuno A
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1035-9. PubMed ID: 20567103
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Takeda M; Okamoto I; Hirabayashi N; Kitano M; Nakagawa K
Lung Cancer; 2011 Jul; 73(1):103-9. PubMed ID: 21111509
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
[TBL] [Abstract][Full Text] [Related]
8. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.
Kai K; Kitajima Y; Hiraki M; Satoh S; Tanaka M; Nakafusa Y; Tokunaga O; Miyazaki K
Cancer Lett; 2007 Dec; 258(1):45-54. PubMed ID: 17892912
[TBL] [Abstract][Full Text] [Related]
9. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experience of chemotherapy with S-1/CDDP for highly-advanced gastric cancer].
Uchima Y; Kosaka K; Kimura K; Okita Y; Sim JK; Aomatsu N; Hirata K; Lee WH; Lee T; Nishii T; Tei S; Takeuchi K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1287-90. PubMed ID: 20647711
[TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy of S-1/low-dose CDDP/lentinan for advanced gastric cancer].
Hori T; Ikehara T; Takatsuka S; Fukuoka T; Tendo M; Tezuka K; Dan N; Nishino H; Hirakawa K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):293-5. PubMed ID: 21368498
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of S-1 plus weekly CDDP for advanced gastric cancer].
Kemmochi T; Egawa T; Mihara Y; Irino T; Ito Y; Nagashima A; Makino H; Yamamuro W
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2351-3. PubMed ID: 22202379
[TBL] [Abstract][Full Text] [Related]
13. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of patients with advanced gastric cancer undergoing S-1/CDDP combined neoadjuvant chemotherapy].
Kikuchi D; Ishii Y; Saitou M; Yamada M; Takenoshita S
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1113-7. PubMed ID: 21772093
[TBL] [Abstract][Full Text] [Related]
16. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
[TBL] [Abstract][Full Text] [Related]
17. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
19. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of systemic combination therapy with S-1, an oral fluoropyrimidine, and cisplatin for hepatocellular carcinoma with extrahepatic metastases.
Katamura Y; Aikata H; Hashimoto Y; Kimura Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Kawakami Y; Takahashi S; Chayama K
Hepatogastroenterology; 2010; 57(102-103):1272-8. PubMed ID: 21410071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
